Sabrina Pan

Business Development Manager at ImmunAbs Inc.

Speaker

ImmunAbs is a clinical-stage biotechnology located in South Korea. Our organization has been devoted to developing a monoclonal antibody targeting complement C5 to treat severe autoimmune diseases. Current standard of care (SoC) therapies fail to adequately inhibit the complement cascade, leaving patients with residual symptoms. ImmunAbs has completed a phase 1 study in the United States, yielding compelling data demonstrating complete blockage of complement activation.